Kura Oncology KURA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Darlifarnib | $28.05M+5.0% | $26.71M+4.1% | $25.67M+14.8% | $22.36M— | —— | |
| Discovery Stage Program | $6.54M-9.5% | $7.23M+3.4% | $6.99M-0.4% | $7.02M-3.1% | $7.24M+9.4% | |
| Ziftomenib | $149.51M+4.9% | $142.58M+5.7% | $134.85M+18.8% | $113.53M+19.8% | $94.79M+19.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
